anti cancer

Learn about Carboplatin Injection 450 mg, its oncology use, mechanism of action, administration overview, safety monitoring, storage guidance, and regulatory documentation support from Primecare IMPEX. Carboplatin Injection 450 mg – Oncology Medicine Information by Primecare IMPEX Product Profile: Understanding Carboplatin Injection 450 mg Carboplatin Injection 450 mg is an anti-cancer chemotherapy medicine used in oncology treatment protocols under the supervision of qualified healthcare professionals. It belongs to the platinum-based chemotherapy class and is commonly used as part of cancer treatment plans where a physician determines suitability based on diagnosis, patient condition, kidney function, blood counts, and treatment history. Carboplatin is not a self-use medicine. It is administered in a hospital, cancer center, or supervised clinical setting. The medicine is generally given by intravenous infusion and requires professional monitoring before, during, and after administration. Product Overview Product Name: Carboplatin Injection 450 mg Generic Name: Carboplatin Strength: 450 mg Packing Size: 1 Vial Therapeutic Category: Anti-cancer medicine / Oncology chemotherapy Dosage Form: Injection Route of Administration: Intravenous infusion under medical supervision Use: Oncology treatment as prescribed by a qualified cancer specialist Carboplatin Injection 450 mg is used in oncology care as part of physician-directed chemotherapy protocols. It may be used alone or in combination with other anti-cancer medicines depending on cancer type, stage, patient tolerance, laboratory results, and treatment plan. A healthcare professional may consider Carboplatin in treatment protocols for selected cancers where platinum-based chemotherapy is clinically appropriate. The How Carboplatin Works Carboplatin is a platinum-based anti-cancer medicine. It works by interfering with cancer-cell DNA. When cancer-cell DNA is damaged, the cell may lose its ability to divide and multiply normally. This helps slow or stop the growth of cancer cells as part of a complete oncology treatment plan. Carboplatin is considered different from many general medicines because it acts directly on rapidly dividing cells. For this reason, it can also affect normal fast-growing cells in the body, which is why medical monitoring is very important. Carboplatin Injection 450 mg is administered by intravenous infusion. The exact dose is not fixed for every patient. It is calculated by the treating oncologist based on multiple patient-specific factors. Patient diagnosis Cancer type and stage Body size and treatment protocol Kidney function Blood-cell counts Previous chemotherapy exposure Other ongoing medicines Overall health condition Step 1: Prescription and Oncology Evaluation The oncologist confirms whether Carboplatin is suitable for the patient’s treatment plan. Step 2: Pre-Treatment Tests Blood counts, kidney function, liver function, and other relevant tests may be checked before treatment. Step 3: Dose Calculation The dose is calculated by the healthcare provider according to the approved protocol and patient condition. Step 4: Infusion Preparation The injection is prepared by trained healthcare staff using sterile handling procedures. Step 5: Intravenous Infusion Carboplatin is given into the bloodstream through IV infusion in a supervised medical setting. Step 6: Monitoring During Treatment The patient is observed for infusion reactions, tolerance, and immediate side effects. Step 7: Follow-Up Testing Blood counts and organ function may be monitored after treatment to guide the next cycle. Why Choose Primecare IMPEX Primecare IMPEX provides product-information support, documentation coordination, and export-related assistance for oncology medicines as per applicable regulations. The focus is on quality, compliance, transparency, and proper documentation. Primecare IMPEX Highlights Oncology medicine product-information support Export documentation assistance Batch and packing information support Professional communication Regulatory-focused approach Support for destination-wise document requirements Experienced supplier and distributor network from India Primecare IMPEX supports legal and compliant medicine supply only where all required licenses, prescriptions, permissions, and import approvals are available. Contact Primecare IMPEX – Pharmaceutical Exporter from India Business Name: Primecare IMPEX Business Type: Exporter | Supplier | Distributor Product: Carboplatin Injection 450 mg Packing Size: 1 Vial Category: Anti-cancer medicine / Oncology injection Website: www.medicineexporterfromindia.com Email: raakeshkashiwar@gmail.com WhatsApp: +91 9673008130 WhatsApp Link: https://wa.me/919673008130

Canmab Injection 440 MG contains Trastuzumab (r-DNA origin), an anti-cancer medicine used under medical supervision for HER2-positive cancer treatment. Learn indications, mechanism, administration guidance, safety monitoring, storage, documentation, and product profile information from Primecare Impex. Canmab Injection 440 MG – Trastuzumab (r-DNA Origin) for HER2-Positive Cancer Treatment Support Canmab Injection 440 MG is a prescription anti-cancer medicine containing Trastuzumab (r-DNA origin). It belongs to a class of targeted cancer therapies known as HER2-targeted monoclonal antibodies. Canmab is used only under the supervision of a qualified oncologist and trained healthcare team. This medicine is generally associated with HER2-positive cancer treatment, especially where the cancer cells show overexpression of the HER2 receptor. HER2 testing is important before treatment decisions are made. Canmab Injection 440 MG is not a general-use medicine and should never be used without proper diagnosis, prescription, and medical monitoring. Basic Product Information Product Name: Canmab Injection 440 MG Generic Composition: Trastuzumab (r-DNA origin) Strength: 440 MG Packing Size: 1 Vial Therapeutic Category: Anti-cancer medicine Dosage Form: Injection / Infusion preparation Use: HER2-targeted oncology therapy under specialist supervision Administration: By trained healthcare professionals only Prescription Status: Prescription oncology medicine Trastuzumab is a targeted monoclonal antibody designed to act against cancer cells that overexpress the HER2 receptor. HER2 stands for Human Epidermal Growth Factor Receptor 2. In some cancers, HER2 activity may support faster cancer cell growth and survival. Trastuzumab works by targeting HER2-positive cells and helping reduce HER2-driven cancer progression. The term r-DNA origin means the medicine is produced using recombinant DNA biotechnology. This allows the development of a biologic medicine designed to target a specific cancer-related receptor pathway. Canmab Injection 440 MG may be used in oncology treatment plans where trastuzumab therapy is medically appropriate. The final decision depends on the patient’s diagnosis, HER2 test result, cancer stage, treatment history, organ function, and oncologist recommendation. HER2-Positive Breast Cancer Trastuzumab is widely associated with the management of HER2-positive breast cancer. It may be considered in early-stage, locally advanced, or metastatic disease depending on the treatment protocol and medical evaluation. HER2-Positive Metastatic Breast Cancer In advanced or metastatic HER2-positive breast cancer, trastuzumab may be used alone or with other anti-cancer medicines as decided by the oncology team. HER2-Positive Gastric or Gastroesophageal Junction Cancer Trastuzumab may also be used in selected HER2-positive stomach or gastroesophageal junction cancers, usually as part of a specialist-guided treatment plan. Combination Therapy Depending on the case, trastuzumab may be combined with chemotherapy, hormonal therapy, or other oncology medicines. Combination choice should always be made by a qualified oncologist. Canmab Injection 440 MG should not be used for self-treatment. It is not suitable for use without HER2 testing, prescription, cardiac assessment, infusion supervision, and continuous medical monitoring. How Canmab Works Canmab Injection 440 MG contains Trastuzumab, a HER2-targeted monoclonal antibody. Its action is based on targeting the HER2 receptor found on the surface of certain cancer cells. Step 1: HER2 Receptor Identification Some cancer cells have high HER2 receptor expression. These receptors may send growth signals that help cancer cells multiply. Step 2: Trastuzumab Binding Trastuzumab binds to the HER2 receptor on HER2-positive cancer cells. Step 3: Growth Signal Blocking By attaching to HER2, trastuzumab helps reduce HER2-related growth signaling. Step 4: Immune System Support Trastuzumab may also help the body’s immune system identify and attack HER2-positive cancer cells. Step 5: Treatment Response Monitoring The response is monitored through clinical evaluation, imaging, lab testing, and oncologist review. Why Choose Primecare Impex Primecare Impex provides product information and sourcing support for prescription oncology medicines with attention to documentation, handling requirements, and customer communication. Contact Primecare Impex — Pharmaceutical Exporter from India For Canmab Injection 440 MG product information, availability details, documentation support, and prescription-based medicine enquiry, contact Primecare Impex. Website: www.medicineexporterfromindia.com Email: raakeshkashiwar@gmail.com Business Type: Exporter | Supplier | Distributor WhatsApp: +91 9673008130 WhatsApp Link: https://wa.me/919673008130

Learn about Busulfex Injection 10 mL / 6 mg, a busulfan-based anticancer injection used under specialist medical supervision. Understand indications, mechanism, administration overview, safety monitoring, storage, handling, and regulatory documentation for Washington, London UK, Riyadh Saudi Arabia, Canberra Australia, UAE, and Kingston Jamaica. Busulfex Injection contains Busulfan, a cytotoxic anticancer medicine used in carefully controlled hospital and oncology settings. It belongs to the class of medicines known as alkylating agents, which act by damaging DNA inside rapidly dividing cells. Busulfex Injection is not a general-use medicine. It is used only when prescribed and administered by qualified oncology, hematology, or transplant specialists. Because busulfan can strongly affect bone marrow function, it requires strict medical monitoring, hospital-based preparation, and professional administration. Product Overview Product Name: Busulfex Injection Generic Name: Busulfan Injection Strength: 10 mL / 6 mg per mL Packing Size: 1 Vial Dosage Form: Concentrate / Injection for IV infusion after dilution Therapeutic Category: Anticancer Medicine / Alkylating Agent Use: Specialist oncology and transplant-conditioning medicine Busulfex Injection is primarily used in specialist oncology and hematology care. Busulfan is commonly associated with conditioning regimens before hematopoietic stem cell transplantation. It may be used as part of a treatment plan before bone marrow or stem cell transplant procedures, where doctors prepare the patient’s body for transplantation. The exact treatment plan depends on the patient’s diagnosis, body weight, organ function, transplant protocol, and overall medical condition. Common Clinical Contexts Busulfex / Busulfan Injection may be considered in hospital protocols for: Conditioning before hematopoietic stem cell transplantation Certain hematological cancer treatment protocols Specialist oncology and transplant-center treatment plans Doctor-supervised chemotherapy combinations Busulfex contains busulfan, an alkylating agent. Alkylating agents work by attaching chemical groups to DNA. This process interferes with DNA replication and cell division. Cancer cells and bone marrow cells divide rapidly, making them sensitive to busulfan’s action. In transplant conditioning, busulfan helps suppress existing bone marrow activity so that transplanted stem cells can establish themselves. Simple Explanation Busulfex works by: Damaging DNA inside rapidly dividing cells Reducing the ability of abnormal cells to multiply Supporting transplant-conditioning protocols Preparing the body for donor stem cell transplantation when used in approved regimens Because it affects normal bone marrow cells as well, close monitoring is essential. Busulfex Injection should be administered only by qualified medical professionals. It is not given directly as an undiluted injection. It must be diluted according to hospital protocol before intravenous infusion. The dose is calculated by the treating doctor based on clinical factors such as: Patient weight Transplant protocol Liver function Kidney function Blood counts Previous chemotherapy exposure Concomitant medicines Therapeutic drug monitoring requirements, where applicable Important Administration Points For intravenous infusion only Must be diluted before administration Prepared by trained hospital pharmacy or oncology staff Administered in a controlled clinical setting Blood counts and organ function must be monitored Dose adjustment may be required depending on clinical response and toxicity Patients should never attempt to use Busulfex without medical supervision. Why Choose Primecare Impex Primecare Impex provides healthcare-focused product information, documentation support, and regulatory-aware communication for specialty medicines. For prescription oncology products like Busulfex Injection, Primecare Impex emphasizes responsible information sharing, compliance, and licensed medical-channel handling. Primecare Impex Focus Areas Oncology medicine information support Product documentation guidance Temperature-sensitive medicine awareness Export documentation support where legally permitted Healthcare-only communication Compliance-focused process Clear product profile and handling guidance Professional response for international healthcare inquiries Primecare Impex does not encourage self-medication. Prescription anticancer medicines should be used only under specialist medical supervision. Contact Primecare Impex — Pharmaceutical Exporter from India Website: www.medicineexporterfromindia.com Email: raakeshkashiwar@gmail.com Business Type: Exporter | Supplier | Distributor WhatsApp: +91 9673008130 WhatsApp Link: https://wa.me/919673008130

Bleomycin Injection 15 Units – Trusted Anti-Cancer Medicine Information & Regulated Supply Support from India Product Name: Bleomycin Injection 15 Units Generic Name: Bleomycin Sulfate Injection Strength: 15 Units Packing Size: 1 Vial Therapeutic Category: Anti-Cancer Medicine / Cytotoxic Chemotherapy Dosage Form: Injection Use: Used in selected cancer treatment protocols under specialist medical supervision Bleomycin Injection 15 Units is a prescription anti-cancer medicine used in oncology treatment plans. It belongs to a group of medicines known as cytotoxic chemotherapy agents. It is generally administered in hospitals, oncology clinics, or specialist cancer-care settings by trained healthcare professionals. This medicine should never be self-administered. It must be used only when prescribed by an oncologist or qualified medical specialist. The exact dose, route, schedule, and duration depend on the cancer type, patient condition, body surface area, kidney function, lung health, and the complete treatment protocol. Primecare Impex provides medicine information and regulated export support for international buyers, hospitals, clinics, pharmacies, and authorized medicine importers who require proper product documentation and compliant sourcing from India Bleomycin Injection is used as part of selected cancer treatment regimens. It may be used alone in some cases, but more commonly it is used in combination with other chemotherapy medicines depending on the diagnosis and treatment plan. It is important to understand that Bleomycin is not a general wellness medicine, pain medicine, or supportive-care medicine. It is a chemotherapy medicine and must be handled carefully. Bleomycin requires careful monitoring during treatment. The doctor may recommend lung assessment, kidney-function tests, blood tests, and general health monitoring before and during therapy. Patients should immediately inform their healthcare team if they experience breathing difficulty, persistent cough, fever, chills, unusual tiredness, skin reactions, mouth sores, or any severe discomfort after treatment. Bleomycin Injection 15 Units is used in oncology treatment under medical supervision. It may be included in treatment protocols for selected cancers where the oncologist considers it clinically appropriate. Common oncology areas where bleomycin may be considered include: Hodgkin lymphoma treatment protocols Certain non-Hodgkin lymphoma treatment protocols Testicular cancer combination regimens Certain squamous cell cancers Other specialist oncology uses as decided by the treating doctor The exact indication depends on the patient’s diagnosis, stage of disease, treatment plan, and local clinical guidelines. Important note: This product information is for educational and SEO content only. It is not a substitute for medical advice, diagnosis, or treatment. Bleomycin works by interfering with the DNA of cancer cells. Cancer cells grow and divide rapidly. Bleomycin can damage DNA strands inside these cells, which may slow down or stop cancer-cell multiplication. Because it affects rapidly dividing cells, bleomycin can also affect some normal cells in the body. This is why patients may experience side effects and why proper medical monitoring is necessary. The medicine is used carefully because its benefits and risks must be evaluated by the treating oncologist. Bleomycin Injection 15 Units must be administered only under the supervision of a qualified healthcare professional. General administration guidance: The dose is decided by the oncologist. The route is decided according to treatment protocol. The injection is prepared by trained medical staff. The patient is monitored during and after treatment. Dose adjustment may be required in certain patients. Kidney function and lung health may affect treatment decisions. Important patient safety note: Do not self-administer Bleomycin Injection. Do not change the dose, skip medical monitoring, or repeat treatment without doctor approval. Contact Primecare Impex — Pharmaceutical Exporter from India Website: www.medicineexporterfromindia.com Email: raakeshkashiwar@gmail.com Business Type: Exporter | Supplier | Distributor WhatsApp: +91 9673008130 WhatsApp Link: https://wa.me/919673008130 You can contact Primecare Impex through the official website, email, or WhatsApp details listed below.

Learn about Bevatas Injection 400 mg, a bevacizumab concentrate for solution for infusion used in oncology care under medical supervision. Product profile, usage information, safety, storage, regulatory documentation, and Primecare Impex contact details. Bevatas Injection 400 mg – Bevacizumab 400mg/16ml Concentrate for Solution for Infusion for Oncology Care Bevatas Injection 400 mg contains Bevacizumab, a monoclonal antibody used in oncology treatment. It is supplied as a concentrate for solution for infusion and is intended for administration by qualified healthcare professionals in a hospital, oncology clinic, or supervised medical setting. Bevatas belongs to the category of targeted anticancer medicines. Unlike traditional chemotherapy that directly attacks rapidly dividing cells, bevacizumab works by targeting a growth factor involved in the formation of new blood vessels. This helps reduce the blood supply that tumors may need to grow and spread. Basic Product Details Brand Name: Bevatas Generic Name: Bevacizumab Strength: 400 mg / 16 ml Dosage Form: Concentrate for solution for infusion Packing Size: 1 vial Therapeutic Category: Anticancer medicine Route of Administration: Intravenous infusion only Use: Oncology treatment under doctor supervision Bevacizumab is a targeted cancer therapy known as an anti-VEGF monoclonal antibody. VEGF stands for vascular endothelial growth factor, a protein that supports the growth of new blood vessels. Some tumors depend on new blood vessel formation to receive oxygen and nutrients. By blocking VEGF activity, bevacizumab may help slow tumor progression in specific cancers when used as part of a doctor-prescribed treatment plan. Bevatas Injection 400 mg should not be used without a valid medical prescription, oncology evaluation, and professional administration. Bevatas Injection 400 mg contains bevacizumab, which is used in oncology care for selected cancer types depending on the approved indication, local treatment guidelines, and oncologist decision. Bevacizumab may be used in treatment plans for certain cases of: Metastatic colorectal cancer Non-squamous non-small cell lung cancer Recurrent glioblastoma Renal cell carcinoma Ovarian, fallopian tube, or primary peritoneal cancer Cervical cancer Other doctor-approved oncology indications depending on country-specific regulations The actual use depends on medical evaluation, cancer diagnosis, biomarker status where relevant, previous therapy, and local regulatory approval. Bevatas works through the active ingredient bevacizumab. Cancer cells may stimulate the body to create new blood vessels. This process is called angiogenesis. New blood vessels can help tumors receive oxygen and nutrients. Bevacizumab binds to VEGF and reduces its ability to support new blood vessel formation. By blocking VEGF activity, bevacizumab may help limit tumor blood supply and slow cancer growth when used as part of an appropriate oncology treatment plan. This is why bevacizumab is known as an anti-angiogenic targeted therapy. Why Choose Primecare Impex? Primecare Impex supports medicine-related enquiries with a focus on professional communication, product information, documentation awareness, and regulatory compliance. Primecare Impex Highlights Pharmaceutical exporter from India Supplier and distributor support Oncology product information assistance Professional product profile support Documentation-focused communication International enquiry support WhatsApp and email assistance Clear product details for healthcare-related requirements Compliance-aware communication for regulated medicines Bevatas Injection 400 mg product information Bevatas 400 mg bevacizumab injection details Bevacizumab 400mg 16ml concentrate for infusion Bevatas Injection 400 mg oncology medicine profile Bevatas 400 mg anticancer infusion information Bevacizumab concentrate for solution for infusion 400 mg Bevatas 400 mg vial information for oncology care Bevacizumab targeted therapy information Bevatas Injection 400 mg safety and storage details Bevacizumab anti VEGF monoclonal antibody information Bevatas 400mg/16ml infusion product profile Bevatas Injection 400 mg clinical use overview Bevacizumab infusion administration information Bevatas Injection 400 mg for oncologist-supervised treatment Bevatas 400 mg storage and handling information Bevacizumab anticancer medicine information page Bevatas Injection 400 mg Washington information Bevatas Injection 400 mg London UK information Bevatas Injection 400 mg Riyadh Saudi Arabia information Contact Primecare Impex — Pharmaceutical Exporter from India For product-related information and professional enquiries, contact Primecare Impex. Website: www.medicineexporterfromindia.com Email: raakeshkashiwar@gmail.com Business Type: Exporter | Supplier | Distributor WhatsApp: +91 9673008130 WhatsApp Link: https://wa.me/919673008130

Avastin Injection 100 mg – Bevacizumab Targeted Anti-Cancer Therapy Information Product Profile: Understanding Bevacizumab Injection 100 mg Avastin Injection 100 mg contains bevacizumab, a targeted anti-cancer medicine used under specialist oncology supervision. It is supplied as a 1 vial pack and is commonly known as a monoclonal antibody therapy used in selected cancer treatment plans. Avastin is not a general medicine and should not be used without a doctor’s prescription, oncology evaluation, and hospital-based administration plan. It is generally used as part of a complete cancer-treatment protocol, often in combination with chemotherapy or other oncology medicines depending on the cancer type, patient condition, and country-specific approval. Product Name: Avastin Injection 100 mg Generic Name: Bevacizumab Strength: 100 mg Dosage Form: Concentrate for solution for infusion Packing Size: 1 vial Therapeutic Category: Anti-cancer / targeted therapy / monoclonal antibody Route of Use: Intravenous infusion only under medical supervision Use: Anti-cancer medicine for selected oncology indications Avastin 100 mg is used in oncology care for selected cancers where bevacizumab is considered suitable by the treating oncologist. Depending on the approved label in the patient’s country, bevacizumab may be used in treatment plans for certain cases of: Metastatic colorectal cancer Non-small cell lung cancer Renal cell carcinoma Ovarian, fallopian tube, or primary peritoneal cancer Cervical cancer Recurrent glioblastoma Other specialist-approved oncology uses depending on local regulations and clinical judgment Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor, commonly known as VEGF. VEGF helps create new blood vessels. Tumors often need new blood vessels to receive oxygen and nutrients for growth. Avastin works by binding to VEGF and reducing its activity. This may help limit the formation of new blood vessels that support tumor growth. Because of this action, bevacizumab is known as an anti-angiogenic targeted therapy. In simple words, Avastin does not work like ordinary pain medicine or antibiotics. It is a targeted oncology medicine designed to interfere with tumor blood-supply support mechanisms. This is why it must be used only as part of a doctor-supervised cancer-treatment plan. Why Choose Primecare Impex Primecare Impex provides information-focused support for pharmaceutical product enquiries, documentation guidance, and regulated medicine supply requirements. For oncology medicines such as Avastin 100 mg, Primecare Impex focuses on product authenticity, batch clarity, careful handling, and compliance-based communication. Primecare Impex Highlights Pharmaceutical exporter from India Support for regulated product documentation Focus on oncology and specialty medicines Product information support for healthcare-related enquiries Clear communication on packing, strength, and availability Compliance-based approach for prescription medicines Guidance on storage and handling requirements Professional support for lawful pharmaceutical supply needs Contact Primecare Impex – Pharmaceutical Exporter from India Website: www.medicineexporterfromindia.com Email: raakeshkashiwar@gmail.com Business Type: Exporter | Supplier | Distributor WhatsApp: +91 9673008130 WhatsApp Link: https://wa.me/919673008130 Avastin injection 100 mg bevacizumab product information Avastin 100 mg vial anti cancer injection profile Bevacizumab injection 100 mg clinical usage information Avastin 100 mg storage and handling requirements Avastin bevacizumab mechanism of action explained Avastin injection 100 mg safety monitoring guide Bevacizumab 100 mg vial oncology medicine information Avastin 100 mg IV infusion information for cancer care Avastin injection 100 mg side effects and precautions Bevacizumab injection 100 mg regulatory documentation Avastin 100 mg vial cancer treatment information Avastin 100 mg monoclonal antibody injection Bevacizumab anti angiogenic therapy information Avastin injection 100 mg Washington oncology information Avastin injection 100 mg London UK information Avastin 100 mg Riyadh Saudi Arabia product information Avastin 100 mg Canberra Australia oncology information Avastin injection 100 mg UAE cancer medicine information

Extensive Product Profile: Understanding Celzar 200mg Injection Celzar 200mg Injection contains Gemcitabine, an advanced nucleoside metabolic inhibitor. It is globally recognized as a cornerstone antineoplastic therapy prescribed by oncologists worldwide to target, manage, and treat various aggressive forms of solid tumor malignancies. 1. Clinical Indications & Usage Metastatic Breast Cancer: Administered in combination with Paclitaxel as a first-line intervention for patients with metastatic breast cancer after failure of prior anthracycline-based adjuvant chemotherapy. Advanced Non-Small Cell Lung Cancer (NSCLC): Utilized in combination with Cisplatin as first-line treatment for patients with inoperable, locally advanced, or metastatic NSCLC. Ovarian Cancer: Deployed in combination with Carboplatin for the treatment of patients with advanced epithelial ovarian cancer that has recurred at least 6 months after completion of platinum-based therapy. 2. Mechanism of Action: How Celzar Works DNA Synthesis Inhibition: The diphosphate metabolite inhibits ribonucleotide reductase, reducing the cellular pool of essential deoxyribonucleoside triphosphates required for DNA repair and replication. Enzyme Mimicry: As a nucleoside analogue, Gemcitabine is metabolized intracellularly by nucleoside kinases into active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. 3. Administration and Dosing Guide Administration Route: Intravenous (IV) infusion only. It must be prepared by clinical personnel and infused over a strictly monitored period (typically 30 minutes). Altering infusion duration beyond recommended limits can spike toxicities. Clinical Monitoring: Routine baseline assessments and pre-dose evaluations of liver function, kidney function, and absolute blood counts are mandatory before initiating every individual treatment cycle. 4. Safety, Side Effects, and Monitoring Bone Marrow Suppression: Severe myelosuppression (anemia, leukopenia, and thrombocytopenia) is the primary dose-limiting toxicity. Absolute neutrophil counts (ANC) and platelet numbers must be reviewed prior to every infusion. Pulmonary Toxicity: Serious cases of respiratory adverse drug reactions, such as pulmonary edema, interstitial pneumonitis, or Adult Respiratory Distress Syndrome (ARDS), have been reported. Development of a new cough or unexplained dyspnea warrants immediate suspension of the drug. Common Side Effects: Nausea, vomiting, elevated liver transaminases (ALT/AST), transient proteinuria, mild hematuria, alopecia, flu-like symptoms (fever, chills, headache), rash, and peripheral edema. 5. Storage and Handling Specifications Storage Environment: Prior to reconstitution, the dry powder vial must be stored at a stable room temperature below 30°C (86°F). Precautions: Do not freeze the unreconstituted or reconstituted product, as crystallization can occur. Store within the original outer box to block direct UV light or heavy ambient moisture degradation. Keep strictly safe from children and pets. PRESCRIPTION MEDICINE IS : YES Disclaimer: Celzar 200mg Injection is a specialized prescription oncology drug that must only be administered under the direct clinical guidance and physical supervision of a registered medical oncologist in an authorized treatment setting. This information is meant strictly for educational research purposes. Celzar is highly toxic to fetal development; strict non-hormonal contraceptive methods must be pursued during therapy, and breastfeeding is completely contraindicated. 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [GROUP OF PRIME CARE IMPEX PVT. LTD.] 🌐 Corporate Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Entity Type: International Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 https://wa.me/919673008130

Global Patient & Clinician Guide: Celvestrant 250 mg PFS Injection Celvestrant 250 mg Pre-Filled Syringe (PFS) contains Fulvestrant, an advanced, selective antineoplastic estrogen receptor antagonist. Manufactured to meet rigorous global standards by Celon Laboratories Ltd., it serves as a critical endocrine (hormone) therapy used worldwide to manage advanced, hormone-dependent malignancies. 1. Clinical Indications & Usage Hormone Receptor-Positive (HR+) Advanced Breast Cancer: Used as a single agent (monotherapy) to treat postmenopausal women with hormone receptor-positive, locally advanced, or metastatic breast cancer that has progressed following prior anti-estrogen therapy. HR+/HER2-Negative Metastatic Breast Cancer (Combination Therapy): Indicated for use in combination with CDK4/6 inhibitors (such as palbociclib, ribociclib, or abemaciclib) or other targeted anti-cancer agents for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in women. 2. Mechanism of Action: How Celvestrant Works Estrogen Receptor Binding: Fulvestrant functions as a competitive estrogen receptor antagonist, directly attaching to estrogen receptors inside the breast cancer cells with high affinity. Receptor Down-regulation: Beyond simply blocking the receptor, it alters the structural shape of the receptor, causing the cell to degrade it. This process down-regulates (reduces the overall number of) available estrogen receptors over time. Halting Proliferation: By depriving the tumor cells of essential estrogenic signaling pathways, Celvestrant prevents the transcription of estrogen-dependent genes, effectively slowing or stopping the growth and spread of the cancer. 3. Administration and Dosing Guide Administration Route: Celvestrant is strictly formulated for intramuscular (IM) injection into the gluteal muscle (buttock). It must never be given intravenously, subcutaneously, or taken orally. Administration Protocol: The solution must be injected slowly over 1 to 2 minutes by a qualified medical professional. A standard full dose is typically split into two separate 250 mg pre-filled syringes (one slow injection into each buttock). Standard Schedule: The standard adult dosing regimen begins with a loading phase to achieve steady therapeutic levels quickly, followed by maintenance dosing: Day 1: Initial 500 mg dose (two 250 mg injections). Day 15: Second 500 mg loading dose. Day 29: Third 500 mg dose. Maintenance Phase: 500 mg administered once every 28 days thereafter. 4. Safety, Side Effects, and Clinical Monitoring Injection Site Reactions: Due to the volume and intramuscular nature of the medication, localized pain, swelling, transient inflammation, sciatica, or bruising at the injection site are among the most common physical reactions. Bleeding Risks: Caution must be exercised if a patient has an underlying bleeding disorder or is taking systemic anticoagulants (blood thinners), due to the physical risk of deep muscular hematoma from the intramuscular injection. Common Side Effects: Hot flashes, generalized fatigue (weakness), nausea, vomiting, decreased appetite, joint and bone pain (musculoskeletal pain), back pain, headache, diarrhea, constipation, urinary tract infections, and skin rashes. 5. Storage and Handling Specifications Environmental Protection: Keep the pre-filled syringes securely enclosed in their original manufacturer carton to protect the solution from direct light exposure and excessive moisture. Temperature Management: Celvestrant 250 mg PFS must be stored in a secure refrigerator between 2°C and 8°C (36°F to 46°F). It must never be allowed to freeze. Safety Precaution: Store strictly out of sight and reach of children and domestic animals. Clinical Disclaimer: This comprehensive profile is compiled strictly for educational, scientific research, and informational purposes. Celvestrant 250 mg PFS Injection is a highly specialized oncology prescription medicine. It must be administered exclusively by a trained healthcare professional (doctor or nurse) in a clinical setting. Self-administration is strictly prohibited. PRESCRIPTION MEDICINE: YES 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Corporate Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Product Profile: Celplat 50mg Injection Celplat 50mg Injection contains Cisplatin, an advanced, gold-standard platinum-based alkylating antineoplastic agent. Formulated to the highest global pharmaceutical benchmarks by Celon Laboratories Ltd., this high-strength cytotoxic injection is widely prescribed by oncology specialists globally to treat aggressive, advanced solid tumors and mutation-specific malignancies. 1. Clinical Indications & Usage Advanced Testicular Cancer: Deployed as established first-line combination therapy for patients with advanced or metastatic testicular germ cell tumors who have already undergone appropriate surgical resection or radiation. Advanced Ovarian Cancer: Indicated as primary combination therapy with other approved chemotherapeutic agents, or as single-agent systemic treatment, for patients with advanced or recurrent ovarian malignancies who have previously received platinum-based therapies. Squamous Cell Head and Neck Cancers: Administered as a potent radiosensitizer alongside radiotherapy or systemic combinations to combat advanced epithelial tumors of the head, neck, nasopharynx, and oral cavity. 2. Mechanism of Action: How Celplat Works Aquation and Activation: Once inside the low-chloride environment of the cancer cell cytoplasm, the Cisplatin molecule undergoes activation (aquation), losing its chloride leaves to become a highly reactive, positively charged platinum complex. DNA Cross-Linking: The activated platinum complex binds directly to the cellular genetic blueprint, forming strong covalent bonds primarily at the N-7 position of guanine and adenine bases. This results in tight intra-strand and inter-strand DNA cross-links. Replication Roadblock: These heavy structural cross-links fundamentally warp the double-helix geometry of the DNA. This creates an impassable roadblock that halts replication forks, stops RNA transcription, and completely suppresses further DNA synthesis. 3. Administration and Dosing Guide Administration Route: Celplat 50mg is formulated strictly for intravenous (IV) infusion. It must be diluted in an appropriate volume of sodium chloride-containing sterile fluids and administered via a secure intravenous line. It is highly unsafe for direct push and must never be self-administered. Intensive Hydration Framework: To protect the kidneys, patients must undergo intensive intravenous pre-hydration with 1 to 2 liters of fluid infused over 8 to 12 hours before receiving the drug. Adequate hydration and high urine output must be strictly maintained for 24 hours post-infusion, often accompanied by mannitol or furosemide-induced diuresis. 4. Safety, Side Effects, and Monitoring Severe Nephrotoxicity (Kidney Damage): Dose-related and cumulative renal tubular damage is the major dose-limiting risk of Cisplatin. Comprehensive pre-dose kidney function profiles (Blood Urea Nitrogen [BUN], Serum Creatinine, and Creatinine Clearance) alongside serum electrolyte checks (Magnesium, Potassium, Calcium) are mandatory before starting every treatment cycle. Severe Ototoxicity (Hearing Damage): This medication can cause significant inner ear toxicity, manifesting as severe tinnitus (ringing in the ears), high-frequency hearing loss (4,000 to 8,000 Hz range), or occasional deafness. Audiometric testing should be performed at baseline and before every subsequent dose. 5. Storage and Handling Specifications Temperature Frame: Store Celplat 50mg vials at controlled room temperature between 15°C to 25°C (59°F to 77°F). Do not refrigerate or freeze, as low temperatures will cause the active platinum compound to precipitate out of the solution. Environmental Safeguards: Keep the vials sealed securely inside their original manufacturer packaging carton to shield the medicine from direct UV light exposure. Handle with strict cytotoxic precautions, using appropriate protective equipment, and keep entirely out of reach of children. Prescription Medicine: Yes Clinical Disclaimer: This profile is compiled strictly for informational, educational, and international sourcing transparency. Celplat 50mg Injection is a specialized oncology drug available exclusively under valid clinical prescription. It must be prepared, handled, and administered solely under the direct guidance of a registered oncology specialist in a qualified hospital or clinical infusion environment. 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Product Profile: Celplat 10mg Injection Celplat 10mg Injection contains Cisplatin, an advanced, gold-standard platinum-based alkylating antineoplastic agent. Formulated to the highest global pharmaceutical standards by Celon Laboratories Ltd., this specialized chemotherapy agent is widely used by oncologists worldwide to treat and manage aggressive solid tumors and mutation-specific malignancies. 1. Clinical Indications & Usage Advanced Testicular Cancer: Used in highly effective combination regimens for patients with advanced testicular tumors who have already undergone appropriate surgical or radiotherapeutic interventions. Advanced Ovarian Cancer: Indicated as combination therapy with other approved chemotherapeutic agents or as a single agent for patients with advanced ovarian tumors who have previously received platinum-based or systemic therapies. Advanced Bladder Cancer: Deployed as a single agent or combination framework for patients with locally advanced or metastatic bladder cancer who are no longer candidates for localized surgery or radiotherapy. Head and Neck Epithelial Tumors: Administered alongside radiotherapy or systemic regimens to combat advanced squamous cell carcinomas of the head and neck. 2. Mechanism of Action: How Celplat Works DNA Cross-Linking: Once inside the cytoplasm, the active Cisplatin molecule sheds its chloride ions and binds directly to the cellular genetic blueprint. It hooks onto guanine and adenine bases, creating tight intra-strand and inter-strand DNA cross-links. Replication Roadblock: These heavy platinum cross-links fundamentally warp the double-helix structure of the DNA. This creates an unpassable block that stops replication forks and suppresses DNA synthesis. Apoptosis Induction: Because rapidly dividing cancer cells cannot repair these severe, platinum-induced structural defects, the cellular check-points trigger a distress cascade. This forces the damaged cancer cells into programmed cell death (apoptosis), halting tumor growth. 3. Administration and Dosing Guide Administration Route: Celplat 10mg is formulated strictly for intravenous (IV) infusion. It must be diluted in appropriate sterile saline lines and administered by a clinical team. It is highly unsafe for direct push and must never be self-administered. Hydration Framework: To protect kidney health, patients must receive intensive intravenous hydration with fluids (often containing mannitol) for 8 to 12 hours before the infusion, and maintain high fluid volume and urine output for 24 hours post-treatment. 4. Safety, Side Effects, and Monitoring Severe Nephrotoxicity (Kidney Damage): Cumulative and dose-related renal tubular damage is a major dose-limiting risk. Comprehensive baseline and pre-dose kidney function profiles (Blood Urea Nitrogen, Serum Creatinine, and Creatinine Clearance) are mandatory before every cycle. Ototoxicity (Hearing Impairment): This medication can cause significant inner ear damage, resulting in severe tinnitus (ringing in the ears), high-frequency hearing loss, or occasional deafness. Pre-treatment and periodic audiometric testing are highly recommended . Bone Marrow Suppression: It temporarily lowers the production of red blood cells, infection-fighting white blood cells, and platelets, increasing the risks of anemia, infections, and bleeding. Baseline and weekly Complete Blood Counts (CBC) are required. 5. Storage and Handling Specifications Temperature Frame: Store Celplat 10mg vials at controlled room temperature between 15°C to 25°C (59°F to 77°F). Do not refrigerate or freeze, as low temperatures will cause the platinum compound to precipitate out of the solution. Environmental Safeguards: Keep the vials sealed securely inside their original manufacturer packaging. Protect the medicine from direct UV light exposure. Handle with strict cytotoxic precautions and keep entirely out of reach of children. Prescription Medicine: Yes Clinical Disclaimer:This profile is compiled strictly for informational, educational, and international sourcing transparency. Celplat 10mg Injection is a specialized oncology drug available exclusively under valid clinical prescription. It must be prepared, handled, and administered solely under the direct guidance of a registered oncology specialist in a qualified clinical environment 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Product Profile: Celostatin LAR 30mg Injection Celostatin LAR 30mg contains Octreotide Acetate, an advanced, long-acting synthetic octapeptide that mimics natural somatostatin. Developed under stringent international quality controls by Celon Laboratories Ltd., this specialized Long-Acting Release (LAR) injection is prescribed globally by endocrinologists and oncologists to manage neuroendocrine tumors, growth hormone disorders, and specific gastrointestinal complications. 1. Clinical Indications & Usage Acromegaly: Used for long-term maintenance therapy in adult patients who have responded adequately to or are stabilized on immediate-release subcutaneous octreotide. It helps normalize excess growth hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) levels when surgical resection or radiotherapy is inappropriate or ineffective. Severe Diarrhea and Flushing associated with Metastatic Carcinoid Tumors: Deployed for the symptomatic control of severe watery diarrhea and intense skin flushing episodes linked to metastatic neuroendocrine carcinoid syndrome. Vasoactive Intestinal Peptide-Secreting Tumors (VIPomas): Indicated for the management of profuse, watery diarrhea and associated electrolyte imbalances caused by VIP-secreting pancreatic adenomas. Gastro-Esophageal Variceal Bleeding: Utilized to control acute hemorrhage and prevent re-bleeding from ruptured esophageal varices in patients with chronic liver disease or cirrhosis. 2. Mechanism of Action: How Celostatin LAR Works Somatostatin Receptor Agonism: It binds selectively and with higher potency than natural somatostatin to specific somatostatin receptors (primarily SSTR2 and SSTR5) located throughout the pituitary gland and gastrointestinal tract. Hormonal Suppression: This receptor binding strongly suppresses the excessive secretion of anterior pituitary hormones, effectively reducing circulating levels of growth hormone (GH) and thyroid-stimulating hormone (TSH). Splanchnic Vasoconstriction: To combat variceal bleeding, the active drug induces selective constriction (narrowing) of the splanchnic blood vessels. This safely limits blood inflow to the portal vein system, reducing pressure and halting active hemorrhage in the food pipe. 3. Administration and Dosing Guide Professional Administration: The injection must be prepared and delivered solely by a trained healthcare professional. It is packaged as a comprehensive kit containing a vial of octreotide microspheres, a prefilled vehicle syringe, a vial adapter, and a specialized administration needle. Standard Schedule: For acromegaly and neuroendocrine tumors, the standard clinical starting dosage is 20mg or 30mg administered once every 4 weeks (28 days) for long-term management. Dosages are adjusted symmetrically by the specialist based on therapeutic hormone levels and clinical symptom response. 4. Safety, Side Effects, and Monitoring Gallbladder and Liver Alterations: Long-term utilization inhibits gallbladder contractility and decreases bile secretion, which frequently leads to cholelithiasis (gallstone formation) or biliary sludge. Periodic ultrasound examinations of the gallbladder are clinically advised. Glucose Regulation Instability: Because octreotide suppresses the release of both insulin and glucagon, it can cause unpredictable shifts in blood sugar levels, resulting in either hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar). Regular blood glucose monitoring is mandatory, especially for diabetic patients. 5. Storage and Handling Specifications Cold Chain Logistics: Store Celostatin LAR 30mg kits under strict refrigeration between 2°C to 8°C (36°F to 46°F). Do not freeze. Environmental Safeguards: Keep the kit sealed within its original manufacturer carton box to shield the light-sensitive components from direct UV light exposure. Prior to administration, the kit may be allowed to reach room temperature for roughly 30 to 60 minutes to minimize injection site discomfort, but it must be injected immediately after reconstitution. Keep entirely out of reach of children. Prescription Medicine: Yes Clinical Disclaimer: This profile is compiled strictly for informational, commercial educational research, and global sourcing transparency. Celostatin LAR 30mg Injection is a controlled, high-specialty prescription drug. It must be dispensed, reconstituted, and administered exclusively under the direct supervision of a registered endocrinologist, oncologist, or qualified gastroenterology clinician. 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Product Profile: Celomide 25mg Capsule Celomide 25mg Capsule contains Lenalidomide, a highly potent small-molecule immunomodulatory agent (IMiD) with powerful anti-angiogenic and direct anti-cancer activities. Formulated under strict international pharmaceutical regulatory benchmarks by Celon Laboratories Ltd., this oral targeted therapeutic option is widely utilized by oncologists globally to manage aggressive plasma cell dyscrasias and complex bone marrow disorders. 1. Clinical Indications & Usage Multiple Myeloma (MM): Prescribed in combination with dexamethasone or as part of highly effective triplet chemotherapy combinations for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. The 25mg capsule typically serves as the standard starting therapeutic dose for the active phase of 28-day treatment cycles. Myelodysplastic Syndromes (MDS): Deployed to manage transfusion-dependent anemia in patients with low- to intermediate-1-risk MDS associated with a cytogenetic anomaly known as the deletion 5q (del 5q) chromosomal defect. Mantle Cell Lymphoma (MCL): Authorized for adult patients with mantle cell lymphoma whose disease has returned, relapsed, or progressed following at least one prior intensive systemic treatment (typically including a proteasome inhibitor like bortezomib). 2. Mechanism of Action: How Celomide Works Cereblon-Mediated Degradation: The drug binds directly to Cereblon (CRBN), a substrate adapter within the intracellular E3 ubiquitin ligase enzyme network. This structural binding forces the rapid degradation of essential lymphoid transcription proteins (Ikaros and Aiolos). Immune System Modulation: By shifting these cellular pathways, Celomide generates an aggressive immune up-regulation. It dramatically triggers the activation and proliferation of the patient's native T-cells and Natural Killer (NK) cells, vastly optimizing the body's natural baseline capability to clear floating tumor populations. Direct Apoptosis Induction: It induces direct cell-cycle arrest in sensitive multiple myeloma and lymphoma cells, stopping replication and driving mutated lines into rapid programmed cell death. 3. Administration and Dosing Guide Administration Route: Celomide 25mg is strictly an oral capsule formulation. The capsule must be swallowed whole with a glass of water at the exact same time every day. It should never be chewed, crushed, split, or opened. Caregivers must avoid direct skin contact or inhalation exposure to the powder contents of damaged capsules. Cyclical Treatment Schedules: For multiple myeloma and lymphoma, the conventional starting regimen involves taking a 25mg capsule once daily on Days 1 through 21 of repeated 28-day treatment cycles, followed by a mandatory 7-day rest window (Days 22–28) to facilitate bone marrow recovery. Dosing adjustments are strictly managed by the treating oncologist. 4. Safety, Side Effects, and Monitoring Severe Bone Marrow Suppression: This medication frequently induces substantial cytopenias. This includes severe neutropenia (profound drop in white blood cells, spiking infection risks) and thrombocytopenia (low platelet counts, raising the risk of bleeding and bruising). Weekly or monthly Complete Blood Counts (CBC) are mandatory. Thromboembolic Hazards: There is an escalated risk of developing dangerous blood clots, including Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or arterial blockages (stroke/myocardial infarction). Prophylactic blood thinners are routinely co-prescribed. Common Side Effects: Chronic fatigue, diarrhea or constipation, muscle cramps, localized skin rashes, generalized itching, nausea, headache, dizziness, and peripheral edema (fluid retention in the limbs). 5. Storage and Handling Specifications Climate Parameters: Store Celomide 25mg capsules safely below 30°C (86°F) in a dry, dark, temperature-controlled environment. Protective Shields: Keep capsules sealed tightly inside their original manufacturer packaging. Protect the medication from high ambient humidity, ambient moisture, and direct UV light exposure. Keep strictly out of reach of children and domestic pets. Prescription Medicine: Yes Clinical Disclaimer: This profile is compiled strictly for informational, educational, and international sourcing transparency. Celomide 25mg Capsule is a highly restricted, specialized oncology drug available exclusively under valid medical prescription. It must be managed, dispensed, and utilized solely under the direct guidance of a registered oncology specialist. 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130